Molecular basis of the interaction of the human tyrosine phosphatase PTPN3 with the hepatitis B virus core protein.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
13 01 2021
Historique:
received: 24 07 2020
accepted: 10 12 2020
entrez: 14 1 2021
pubmed: 15 1 2021
medline: 18 8 2021
Statut: epublish

Résumé

Interactions between the hepatitis B virus core protein (HBc) and host cell proteins are poorly understood, although they may be essential for the propagation of the virus and its pathogenicity. HBc has a C-terminal PDZ (PSD-95, Dlg1, ZO-1)-binding motif (PBM) that is responsible for interactions with host PDZ domain-containing proteins. In this work, we focused on the human protein tyrosine phosphatase non-receptor type 3 (PTPN3) and its interaction with HBc. We solved the crystal structure of the PDZ domain of PTPN3 in complex with the PBM of HBc, revealing a network of interactions specific to class I PDZ domains despite the presence of a C-terminal cysteine in this atypical PBM. We further showed that PTPN3 binds the HBc protein within capsids or as a homodimer. We demonstrate that overexpression of PTPN3 significantly affects HBV infection in HepG2 NTCP cells. Finally, we performed proteomics studies on both sides by pull-down assays and screening of a human PDZ domain library. We identified a pool of human PBM-containing proteins that might interact with PTPN3 in cells and that could be in competition with the HBc PBM during infection, and we also identified potential cellular partners of HBc through PDZ-PBM interactions. This study opens up many avenues of future investigations into the pathophysiology of HBV.

Identifiants

pubmed: 33441627
doi: 10.1038/s41598-020-79580-9
pii: 10.1038/s41598-020-79580-9
pmc: PMC7806630
doi:

Substances chimiques

Hepatitis B Core Antigens 0
Viral Core Proteins 0
Tyrosine 42HK56048U
PTPN3 protein, human EC 3.1.3.48
Protein Tyrosine Phosphatase, Non-Receptor Type 3 EC 3.1.3.48
Protein Tyrosine Phosphatases EC 3.1.3.48

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

944

Références

J Biol Chem. 2016 Aug 5;291(32):16699-708
pubmed: 27246854
J Hepatol. 2016 Apr;64(1 Suppl):S49-S59
pubmed: 27084037
Nat Methods. 2015 Aug;12(8):787-93
pubmed: 26053890
J Gen Virol. 2005 Jan;86(Pt 1):75-84
pubmed: 15604433
EMBO J. 2002 Dec 2;21(23):6505-14
pubmed: 12456657
J Virol. 2011 Nov;85(22):11544-56
pubmed: 21775458
Pathogens. 2016 Jan 18;5(1):
pubmed: 26797638
J Virol. 2014 Aug;88(16):8754-67
pubmed: 24850741
PLoS Pathog. 2011 Nov;7(11):e1002388
pubmed: 22114561
Proteins. 2005 Jun 1;59(4):687-96
pubmed: 15815974
EMBO J. 2002 Mar 1;21(5):876-84
pubmed: 11867516
Biophys J. 2000 Mar;78(3):1606-19
pubmed: 10692345
Sci Signal. 2012 Aug 14;5(237):ra58
pubmed: 22894835
J Gen Virol. 1990 Nov;71 ( Pt 11):2755-9
pubmed: 2254755
Eur J Immunol. 2000 May;30(5):1318-25
pubmed: 10820377
J Biomed Sci. 2007 Nov;14(6):731-44
pubmed: 17588219
J Gen Virol. 1979 Nov;45(2):509-14
pubmed: 541667
Hepatology. 2009 May;49(5 Suppl):S56-60
pubmed: 19399807
J Hepatol. 2017 Nov;67(5):1051-1061
pubmed: 28673770
PLoS One. 2015 Jul 02;10(7):e0131605
pubmed: 26135398
J Virol. 2001 Nov;75(22):10779-86
pubmed: 11602719
J Virol. 2004 Nov;78(22):12366-77
pubmed: 15507623
Gastroenterology. 2014 May;146(5):1397-407
pubmed: 24503127
Sci Signal. 2010 Jan 19;3(105):ra5
pubmed: 20086240
PLoS Pathog. 2019 Jul 29;15(7):e1007945
pubmed: 31356623
J Biol Chem. 2004 Feb 27;279(9):7760-9
pubmed: 14672952
Antiviral Res. 2018 Jan;149:211-220
pubmed: 29183719
J Biol Chem. 1997 Oct 24;272(43):27281-7
pubmed: 9341175
Sci Rep. 2019 May 15;9(1):7438
pubmed: 31092861
J Virol. 1992 Jul;66(7):4107-16
pubmed: 1602535
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Nat Struct Biol. 1999 May;6(5):417-21
pubmed: 10331866
J Virol. 1990 Jul;64(7):3319-30
pubmed: 2191149
Cancer Res. 2010 Apr 1;70(7):2901-10
pubmed: 20332238
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Structure. 2011 Oct 12;19(10):1518-24
pubmed: 22000519
Antiviral Res. 2019 Dec;172:104618
pubmed: 31600532
J Biol Chem. 1999 Jun 18;274(25):17806-12
pubmed: 10364224
Virol J. 2011 Mar 14;8:118
pubmed: 21401943
Science. 2004 May 21;304(5674):1164-6
pubmed: 15155950
PLoS One. 2013 Sep 06;8(9):e69729
pubmed: 24039702
BMC Bioinformatics. 2010 Jun 30;11:357
pubmed: 20591147
Science. 1997 Jan 3;275(5296):73-7
pubmed: 8974395
J Hepatol. 2019 Aug;71(2):289-300
pubmed: 31077792
Nat Protoc. 2016 Dec;11(12):2301-2319
pubmed: 27809316
Methods Enzymol. 2003;370:430-44
pubmed: 14712665
J Biol Chem. 2007 Nov 30;282(48):35405-15
pubmed: 17921143
PLoS Pathog. 2016 Sep 20;12(9):e1005854
pubmed: 27649450
Methods Enzymol. 2014;541:3-10
pubmed: 24674058
Genet Test Mol Biomarkers. 2015 Jun;19(6):283-7
pubmed: 25874746
Biochemistry. 2009 Mar 3;48(8):1736-42
pubmed: 19196007
Endocr Relat Cancer. 2014 Oct;21(5):R345-56
pubmed: 24981109
J Biol Chem. 2003 Mar 7;278(10):8501-7
pubmed: 12493751
Oncogene. 1998 Feb 5;16(5):643-54
pubmed: 9482110
J Virol. 2013 Apr;87(8):4360-71
pubmed: 23388725
Oncogene. 2015 Jul;34(29):3791-803
pubmed: 25263444
Biochem Biophys Res Commun. 2006 Oct 6;348(4):1455-62
pubmed: 16930557
J Virol. 2007 Mar;81(5):2231-9
pubmed: 17166906
J Virol. 2005 Apr;79(7):4229-37
pubmed: 15767424
Mod Pathol. 2004 Oct;17(10):1169-79
pubmed: 15218507
World J Gastroenterol. 2007 Jan 7;13(1):65-73
pubmed: 17206755
Cell Syst. 2017 Apr 26;4(4):430-444.e5
pubmed: 28330616
Oncogene. 2011 Apr 7;30(14):1706-15
pubmed: 21119599
J Biol Chem. 2002 Nov 8;277(45):42463-70
pubmed: 12207026
PLoS Pathog. 2018 Dec 19;14(12):e1007488
pubmed: 30566530
PLoS One. 2013 Nov 18;8(11):e80769
pubmed: 24260477
J Gastroenterol. 1994 Dec;29(6):727-32
pubmed: 7874267
Gastroenterology. 2014 Sep;147(3):719-20
pubmed: 25075940
Biophys J. 2011 Nov 16;101(10):2476-84
pubmed: 22098746
Antiviral Res. 2015 Sep;121:82-93
pubmed: 26129969
Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12735-40
pubmed: 16908842
Methods Mol Biol. 2019;2025:439-476
pubmed: 31267466
Arch Virol. 2010 Feb;155(2):247-50
pubmed: 20091192
J Immunol. 2007 Mar 15;178(6):3680-7
pubmed: 17339465
Oncol Rep. 2014 Jun;31(6):2797-803
pubmed: 24788990

Auteurs

Mariano Genera (M)

Channel-Receptors Unit, UMR 3571, CNRS, Institut Pasteur, 75015, Paris, France.
Complexité du Vivant, Sorbonne Université, 75005, Paris, France.

Barbara Quioc-Salomon (B)

UMR 3569, CNRS, 75015, Paris, France.
Department of Virology, Institut Pasteur, Paris, France.
Université Paris Diderot, Sorbonne Paris Cité, Paris, France.

Antonin Nourisson (A)

Channel-Receptors Unit, UMR 3571, CNRS, Institut Pasteur, 75015, Paris, France.

Baptiste Colcombet-Cazenave (B)

Channel-Receptors Unit, UMR 3571, CNRS, Institut Pasteur, 75015, Paris, France.
Complexité du Vivant, Sorbonne Université, 75005, Paris, France.

Ahmed Haouz (A)

Crystallography Platform-C2RT, Department of Structural Biology and Chemistry, CNRS, UMR-3528, Institut Pasteur, 75015, Paris, France.

Ariel Mechaly (A)

Crystallography Platform-C2RT, Department of Structural Biology and Chemistry, CNRS, UMR-3528, Institut Pasteur, 75015, Paris, France.

Mariette Matondo (M)

Proteomics Platform, Mass Spectrometry for Biology Utechs (MSBio), USR 2000, CNRS, Institut Pasteur, 75724, Paris, France.

Magalie Duchateau (M)

Proteomics Platform, Mass Spectrometry for Biology Utechs (MSBio), USR 2000, CNRS, Institut Pasteur, 75724, Paris, France.

Alexander König (A)

Applied Molecular Virology Laboratory, Institut Pasteur Korea, 696 Sampyung-dong, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea.

Marc P Windisch (MP)

Applied Molecular Virology Laboratory, Institut Pasteur Korea, 696 Sampyung-dong, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea.

Christine Neuveut (C)

UMR 3569, CNRS, 75015, Paris, France.
Department of Virology, Institut Pasteur, Paris, France.
Institute of Human Genetics, 141 rue de la Cardonille, 34090, Montpellier, France.

Nicolas Wolff (N)

Channel-Receptors Unit, UMR 3571, CNRS, Institut Pasteur, 75015, Paris, France.

Célia Caillet-Saguy (C)

Channel-Receptors Unit, UMR 3571, CNRS, Institut Pasteur, 75015, Paris, France. celia.caillet-saguy@pasteur.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH